login
Password reminder
Interventional News
Contact the editor Visit Interventional News Twitter feed Visit Interventional News Facebook page
 

FDA grants priority review for rivaroxaban supplemental new drug application for the treatment DVT and PE


Tuesday, 10 Jul 2012 12:58

The US Food and Drug Administration (FDA) has assigned a priority review designation to the supplemental new drug applications (sNDAs) filed on 2 May 2012 for rivaroxaban  (Xarelto, Bayer/Janssen), an oral anticoagulant, seeking new indications to treat patients with deep vein thrombosis(DVT), pulmonary embolism (PE), and to prevent recurrent deep vein thrombosis and pulmonary embolism. 


The FDA grants priority review to medicines that offer major advances in care or provide a treatment where no adequate therapy exists. Under the prescription drug user fee act (PDUFA), FDA will aim to complete its review within six months from the receipt of the sNDA submission, rather than the standard 10 month review cycle.

“We are delighted to have received a priority review designation for Xarelto for the treatment of pulmonary embolism and deep vein thrombosis, and also to prevent the recurrence of these conditions. Each year an estimated 900,000 Americans experience a DVT or PE, and one third of those events are fatal. If approved for these indications, Xarelto has the potential to address critical unmet needs in treating patients with these serious medical conditions,” said Paul Burton, vice president, Cardiovascular Franchise Medical Leader, Janssen R&D.


The submissions are supported by data from the global EINSTEIN programme, which includes two phase 3 studies evaluating the safety and efficacy of rivaroxaban in the treatment of patients with acute symptomatic DVT or PE and the prevention of recurrent events in these patients. A third phase 3 study evaluated the safety and efficacy of rivaroxaban in the long-term prevention of recurrent DVT and PE. In total, these phase 3 studies included more than 9,400 patients.


Separately, Janssen R&D announced it is withdrawing the sNDA for the use of rivaroxaban to reduce the risk of stent thrombosis in patients with acute coronary syndrome (ACS). The company is withdrawing this sNDA because it is contingent on a separate sNDA, for rivaroxaban to reduce of the risk of secondary cardiovascular events in patients with ACS, which Janssen R&D received a complete response letter from the FDA on 21 June 2012. Data from the ATLAS ACS 2 TIMI 51 trial support both sNDAs.


“We remain confident in the overall study results from the ATLAS ACS 2 TIMI 51 trial, including the observed reduction in stent thrombosis that formed the basis for this separate sNDA,” said Burton. “Our top priority is to work with FDA on our original sNDA for ACS and submit our reply to the complete response letter as soon as possible. We plan to resubmit the sNDA for stent thrombosis at the same time.”




Add New Comment

Related Items


Most popular


First implant completed in thoracoabdominal aortic aneurysm clinical study
Wednesday, 13 Jan 2016
The first US implant of the Gore Excluder thoracoabdominal branch endoprosthesis has taken place during a clinical study of the treatment of aortic aneurysms involving the visceral branch vessels. First implant completed in thoracoabdominal aortic aneurysm clinical study

Systematic review of registry data suggests stroke or death rate after carotid stenting “significantly higher” than after endarterectomy
Monday, 18 Jan 2016
The review, published in the January 2016 issue of the European Journal of Vascular and Endovascular Surgery (EJVES), further concludes that stroke/death rates after carotid stenting often exceed ... Systematic review of registry data suggests stroke or death rate after carotid stenting “significantly higher” than after endarterectomy

Medtronic launches OsteoCool radiofrequency ablation system in the US
Wednesday, 13 Jan 2016
The OsteoCool radiofrequency ablation system is designed to treat patients with painful spinal metastases. The system has been granted US Food and Drug Administration (FDA) 510(k) marketing clearance. Medtronic launches OsteoCool radiofrequency ablation system in the US

Features


Interventional radiology in trauma management
Friday, 05 Feb 2016
The role of interventional radiology in the management of severely traumatised patients began three to four decades ago with the embolization of the internal iliac arteries for massive pelvic ... Interventional radiology in trauma management

Microvascular plugs investigated in embolization of pulmonary arteriovenous malformations
Monday, 30 Nov 2015
Miles Conrad, University of California San Francisco (UCSF), Interventional Radiology section and co-director of the UCSF HHT Centre of Excellence, spoke to Interventional News about a new device ... Microvascular plugs investigated in embolization of pulmonary arteriovenous malformations

Profiles


Gabriel Bartal
Thursday, 26 Nov 2015
“In the early days, I used to have to cut a 7F plastic tube, make side holes, send it off for ... Gabriel Bartal

Lindsay Machan
Thursday, 28 May 2015
“Focusing on maximising rewards has sidelined more ideas than it has helped individual inventors. S... Lindsay Machan

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions